These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34723856)

  • 21. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
    Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL
    AIDS; 2022 Sep; 36(11):1511-1520. PubMed ID: 35466963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
    de Gea Grela A; Martín Carbonero L; Micán R; Bernardino JI; Ramos L; Valencia ME
    Rev Esp Quimioter; 2022 Aug; 35(4):378-381. PubMed ID: 35614862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of enzyme de-induction in a woman with HIV on methadone maintenance switched from nevirapine- to bictegravir-based antiretroviral regimen.
    Cattaneo D; Giacomelli A; Casalini G; Ridolfo AL; Gervasoni C
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1105-1106. PubMed ID: 38526747
    [No Abstract]   [Full Text] [Related]  

  • 24. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
    Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
    Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
    Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
    Stader F; Courlet P; Decosterd LA; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Apr; 109(4):1025-1029. PubMed ID: 33521960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
    Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bictegravir.
    Spagnuolo V; Castagna A; Lazzarin A
    Curr Opin HIV AIDS; 2018 Jul; 13(4):326-333. PubMed ID: 29746268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
    Roa PE; Bazzi R
    Int J STD AIDS; 2022 Jan; 33(1):97-98. PubMed ID: 34787026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crushed vs dissolved bictegravir/emtricitabine/tenofovir alafenamide.
    Johnson TM; Rivera CG
    Am J Health Syst Pharm; 2023 Feb; 80(4):180-181. PubMed ID: 36377971
    [No Abstract]   [Full Text] [Related]  

  • 32. Weighing considerations with newer antiretrovirals.
    Venter WDF; Hill A
    Lancet HIV; 2020 Jun; 7(6):e374-e375. PubMed ID: 32504568
    [No Abstract]   [Full Text] [Related]  

  • 33. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
    Hoffmann C; Schewe K; Fenske S; Buhk T; Sabranski M; Adam A; Hansen S; Stellbrink HJ
    Antivir Ther; 2020; 25(2):83-90. PubMed ID: 32235038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achievement of virologic suppression with HIV antiretroviral therapy in a patient also taking multiple daily cation supplement doses: A case report and review of the literature.
    Buscemi L; Mossholder B
    Am J Health Syst Pharm; 2023 Feb; 80(4):196-199. PubMed ID: 36306472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
    Acosta RK; Chen GQ; Chang S; Martin R; Wang X; Huang H; Brainard D; Collins SE; Martin H; White KL
    J Antimicrob Chemother; 2021 Jul; 76(8):2153-2157. PubMed ID: 33880558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis.
    Sidman EF; Ondrush NM
    Am J Health Syst Pharm; 2023 Apr; 80(9):e92-e97. PubMed ID: 36373751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
    Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
    Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
    Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
    J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.
    van der Galiën R; Ter Heine R; Greupink R; Schalkwijk SJ; van Herwaarden AE; Colbers A; Burger DM
    Clin Pharmacokinet; 2019 Mar; 58(3):309-323. PubMed ID: 29915921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.